News & Resources
Resources
Curapath Receives Accreditation as a GMP Investigational Drug Product Manufacturer from the Spanish Agency for Medicine and Health Products
Valencia, Spain and Boston, MA, January 26, 2023 – Curapath, a leader in the design, development, andcustom manufacturing of polyamino-acid- and lipid nanoparticle (LNP) delivery
Curapath Announces Collaboration with Afrigen Biologics to Advance Development of African-owned mRNA SARS-CoV-2 Vaccine
Curapath will develop and optimize a process to produce a nanoparticle formulation for the vaccine Valencia, Spain and Boston, MA, November 16, 2022 – Curapath,
Polypeptide Therapeutics Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services
Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned
Curapath Honored By PaternaMajor and Spanish Government Innovation Delegation
PaternaMajor and the Spanish Government Innovation Delegation identified Curapath (formerly PTS), as one of the most innovative companies in the Valencian Community region. The Government delegate
Dr. Vincent Nebot, CTO of Curapath, to present at LNP Summit on October 20, 2022
Curapath, (formerly PTS) a leader in the custom design, development, and end-to-end GMP manufacture of polymer and lipid-based drug delivery systems is partnering with the
